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Aims: Paliperidone palmitate 3-month (PP3M) represents a new long-acting injectable 
antipsychotic therapeutic option. This review aims: 1) to summarize available data relating to 
efficacy, safety, tolerability and costs of PP3M; 2) to describe hospitalization rate, occupational 
status, treatment preference, satisfaction, adherence and caregiver burden of patients with 
schizophrenia who participate in PP3M clinical trials; 3) to examine ethical implications, pros 
and cons of PP3M use and 4) to propose study designs to further assess PP3M.
Methods: On August 21, 2017, a search on PubMed about PPM3, without any filter restriction, 
was conducted and all available records were analyzed. Records written in a language other 
than English were excluded.
Results: Twenty-two records were included in this review: 6 reviews, 1 report, 4 pharmacoki-
netic studies, 2 cost-effectiveness analyses, 1 open-label clinical trial, 2 randomized controlled 
trials (RCTs), 5 studies based on these 2 RCTs and 1 observational study.
Discussion: According to these last 9 studies, when compared with placebo, PP3M showed a 
longer time to relapse and good safety and tolerability profiles. Furthermore, when compared 
with paliperidone palmitate 1 month (PP1M), PP3M treatment showed: 1) non-inferiority in 
terms of efficacy, safety, tolerability, rate of hospitalization, symptomatic and functional remis-
sion, treatment preference and variations of the occupational status; 2) a longer time to relapse 
after treatment discontinuation and 3) a similar reduction of the caregiver burden.
Conclusion: PP3M is the only 3-monthly long-acting injectable antipsychotic available on 
the market. This makes it a unique option of treatment, which could be chosen both in early 
and advanced phases of illness. Nonetheless, longer naturalistic follow-up studies, two-arm 
head-to-head superiority trials and mirror studies, based on real-world samples of patients, are 
needed to further assess long-term safety and advantages of this new option of treatment and 
to define patients’ sub-populations that would most beneficiate from it.
Keywords: PP3M, paliperidone palmitate, LAI, antipsychotic, clinical assessment, advantages 
and disadvantages
Introduction
Schizophrenia is a pervasive psychotic chronic condition, present in all cultures and 
historical periods.1 It is one of the top 20 causes of disability worldwide:2 World 
Health Organization reported that schizophrenia is responsible for 1.1% of the total 
disability-adjusted life years and 2.8% of the years lived with disability.3 It has an 
important impact on patients’ quality of life and mortality, on patients’ families and on 
social and financial costs:1,4,5 in developed countries the disorder justifies 1.5%–3.0% 
of health care expenses.6
Schizophrenia has a prevalence estimated at 0.6%–0.8% and its lifetime prevalence 
is about 1% worldwide.1 Typically, it is preceded by prodromal symptoms leading 
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to a first psychotic episode starting in young adulthood.5,7 
Individuals with schizophrenia have a shorter life expec-
tancy than the general population, an increased risk of 
physical illness, especially cardiovascular disease, as well 
as higher rates of suicide and accidental injury.5,7,8 Episodes 
of partial or full remission broken by relapses characterize 
the long-term course of schizophrenia and difficulties in 
global functioning:5,9 most patients are unable to reach at 
least one milestone, such as being in a stable relationship, 
having full-time competitive employment or having self-
supported independent living.10 Relapse in schizophrenia 
can be destructive often resulting in hospitalization.11–13 
In addition, relapse can be strictly connected with a biological 
risk: it has been hypothesized that active psychosis reflects 
a period of disease progression to the extent that patients 
may not come back to their previous level of functioning 
and can become resistant to treatment.14,15 The early phase of 
schizophrenia, including the first 2 years up to 5 years after 
the onset, is thought to be essential in determining long-term 
prognosis.16 Therefore, a continued treatment from the early 
phases of disease may preserve from structural brain changes 
and progression toward functional deterioration.17–20
Poor adherence to treatment and 
long-acting injectable (LAi) atypical 
antipsychotics
Antipsychotic therapy is the mainstay of schizophrenia 
treatment, and severity and frequency of disease symptoms 
can be adequately managed by adhering to the prescribed 
antipsychotic medication.5,21,22 The most frequent cause of 
relapse in schizophrenia is poor adherence to antipsychotic 
treatment.23,24 When patients discontinue their medications, 
even after the first episode, the risk of symptomatic relapse 
increases dramatically.25 In clinical settings, poor compliance 
is common, especially in the early stages of the disease,26–29 
with between 40% and 60% of patients with schizophrenia 
partially or totally noncompliant with oral antipsychotics.30,31 
It has been highlighted that up to 74% of people affected 
by schizophrenia started to discontinue their medications 
after 18 months and that up to 42% of patients stopped their 
therapy within 1 year after the first psychotic episode.32,33 
Studies using more strict measurement methodology, such 
as pill count, electronic monitoring and blood drug level, 
often indicate higher levels of non-adherence.34–37 Moreover, 
the duration of follow-up certainly has a clear influence 
on the observed frequencies of non-adherence. Therefore, 
it is reasonable to consider that adherence is much lower 
in routine care than in clinical trials.38 Poor adherence has 
serious repercussions on the course of the disease in terms 
of relapses.39,40 Once illness recurrence occurs, the severity 
of symptoms rapidly returns to levels similar to the initial 
psychotic episode.25 This leads to important consequences: 
inability to work and hospitalization in about 70% of the 
cases, attempt to suicide in about 20% of the patients, worsen-
ing of caregivers’ quality of life and higher health care-related 
and indirect costs.39–41 Furthermore, relapses can result in 
poorer long-term outcomes,42 such as disease progression 
and emergent treatment refractoriness.43,44
LAI antipsychotics were developed in order to limit both 
hidden and overt non-adherence to antipsychotic drugs. 
LAIs has some known disadvantages such as pain on the 
injection site, lack of flexibility in dose adjustments and 
patients’ perception of stigma and coercion.40 However, they 
have potential advantages such as complete tracking of the 
drug consumption and full adherence in early stages of the 
disease.45,46 In addition, LAIs do not need daily adminis-
tration, which may be perceived by patients as a practical 
advantage, and minimize the risk of harmful drug use.47,48 
It has also been suggested that pharmacokinetic (PK) dif-
ferences associated with the route of administration may be 
a possible advantage for LAI over oral formulations. The 
higher bioavailability of LAI formulations may help identify 
the lower effective dose, reducing unnecessary toxic serum 
levels of the drug.49 Furthermore, a reduced fluctuation of 
serum drug levels, and therefore a more stable receptor 
occupancy,50 may reduce adverse events.49,51 Moreover, 
in case of sudden treatment interruption, plasmatic drug 
levels would decrease abruptly. On the contrary, after the 
discontinuance of the treatment, LAI antipsychotics assure 
a progressive decrease of the plasma drug levels. This differ-
ence might lower the risk of the so-called “super-sensitivity 
psychosis”, a severe disease relapse triggered by sudden 
antipsychotic withdrawal.52 Furthermore, LAIs facilitate the 
regular contact between patients and physician and allow 
physicians to rule out non-adherence as a cause of relapse. 
At last, should a patient miss an injection, there remains some 
time to act to avert a crisis.53
Among LAIs, second-generation long-acting antipsy-
chotics (SGA-LAIs) combine the advantages of SGAs with 
a long-acting formulation.10 The SGA-LAIs available on the 
market are risperidone LAI (RLAI), olanzapine LAI (OLAI), 
aripiprazole long-acting one month (AOM) and paliperidone 
palmitate (PP) long-acting 1 month (PP1M) and 3 month 
(PP3M). Scientific evidence about superiority of SGA-LAIs 
to SGA oral formulations is controversial. On one hand, 
randomized controlled trials (RCTs), considered to be the 
“gold standard” for clinical trial design, do not support the 
clinical viewpoint that LAI antipsychotics are generally 
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superior to oral formulations in terms of effectiveness, safety 
and tolerability. On the other hand, observational studies 
(eg, cohort and mirror studies), that encompass the concept 
of effectiveness in a naturalistic-pragmatic setting (more 
representative of real-life clinical practice), show a greater 
benefit of LAIs over oral antipsychotics.54–57 RCTs have high 
internal validity and allow specific signal detection in care-
fully selected patient population. Moreover, randomization 
and blinding of the RCTs can adequately control confounding 
effects. However, RCTs are frequently affected by selection 
bias, so they have limited external validity and generalizability 
to a wider clinical patient population.56 Observational natural-
istic studies analyze real-world patients, limiting selection bias 
and improving generalizability and external validity. Also, 
they include pragmatic outcomes such as hospitalizations 
and all-cause treatment discontinuation. Nevertheless, this 
kind of study design can be confounded by factors that vary 
over time and, without a separate control group, this type of 
confounding cannot be controlled for.56 Therefore, in order to 
answer questions of clinical efficacy and effectiveness of LAIs 
in the range of patients generally seen during routine clinical 
practice, both RCTs and naturalistic studies are required.57 
About this topic, a recent meta-analysis of head-to-head RCTs 
comparing the principal SGA-LAIs and their oral counterparts 
highlighted that high-quality evidence suggests that AOM 
may provide some small advantages compared with its oral 
preparation; moderate quality evidence showed that there is no 
clinical benefit for RLAI; evidence for OLAI was imprecise 
and therefore not able to rule out neither clinically meaningful 
superiority nor inferiority vs oral olanzapine; no evidence for 
PP was available in July 2016.54 To achieve stronger evidence 
and recommendations about the use of SGA-LAIs, more head-
to-head comparisons between drugs are expected,57 such as 
the European Long-Acting Antipsychotics in Schizophrenia 
Trial (EULAST), which compares oral and LAI formulations 
of aripiprazole and paliperidone (NCT02146547). These 
investigations will provide data for further meta-analytic 
approaches regarding the relative usefulness of the different 
drugs and formulations available. Future research and experi-
ences will also help to identify which clinical subpopulation 
may obtain greater benefit from these new formulations, 
not only in controlling symptoms but also in terms of 
cognitive performance, functioning, and quality of life.58
Methods
On August 21, 2017, an electronic search on PubMed about 
PP3M, without any filter or MESH restriction, was per-
formed, using the following search string: (“3 months” OR 
“three months” OR “3 monthly” OR “three monthly” OR 
“3-month” OR “three-month” OR “3-monthly” OR “three-
monthly”) AND “paliperidone”. The query translation of 
PubMed search engine was as follows: (“3 months” [All 
Fields] OR “three months” [All Fields] OR “3 monthly” [All 
Fields] OR “three monthly” [All Fields] OR “3-month” 
[All Fields] OR “three-month” [All Fields] OR “3-monthly” 
[All Fields] OR “three-monthly” [All Fields]) AND “pali-
peridone” [All Fields].
This string was developed because, in scientific literature, 
PP3M is called in different ways. In particular, the words 
“three months” (3M) of PP3M have many different spellings 
listed in the proposed string. These spellings were connected 
by “OR” logical operator. This string guaranteed a high-
sensitive search, limiting spelling selection of published 
works indexed in PubMed. Furthermore, an “AND” logical 
operator was used to connect these equivalent spellings of 
3M with the word “paliperidone” of PP3M. This logical 
connective led to a high specific search that selected mostly 
works on topic.
All kinds of publications (ie, original contributions and 
reviews) were included. Publications must concern PP3M 
as principal issue. Publications written in a language other 
than English were excluded.
Results
The search described in the previous section provided 
38 records. Among them, 16 were excluded: 13 because 
they did not concern PP3M and 3 because they were not 
written in English. Thus, this review included 22 records 
indexed on PubMed: 6 reviews, 1 report, 4 PK studies, 
2 cost-effectiveness analyses, 1 open-label clinical trial 
(OCT), 2 double-blind (DB) RCTs, 5 studies based on these 
2 RCTs and 1 observational study. The selection process and 
a schematic representation of the results are represented in 
the literature search flowchart (Figure 1).
This review will describe the main findings relating to 
the formulation, pharmacodynamics, PK, safety, tolerability 
and efficacy of PP3M, followed by a brief presentation about 
practical issues encountered with this new formulation. 
In addition, an overview of possible advantages and disad-
vantages of PP3M compared with PP1M will be reported. 
In the final part of this review, PP3M place in therapy and 
proposals of study designs to further assess this LAI formula-
tion will be discussed. The OCT, the 2 RCTs, the 5 articles 
based on the RCTs and the observational study are sum-
marized in Table 1.
The OCT was a Phase I, single-dose, randomized, open 
label study, conducted to investigate the PK, the safety and 
the tolerability of PP3M in patients with schizophrenia.59 
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The first RCT compared PP3M with placebo in order to 
assess the efficacy and safety of PP3M.60 The second RCT 
aimed to demonstrate non-inferiority of PP3M compared 
with PP1M in terms of relapse rates, changes in Positive and 
Negative Syndrome Scale (PANSS) scores, Clinical Global 
Impression-Severity (CGI-S) score and Personal and Social 
Performance (PSP) score.61 Savitz et al,62 Katz et al,63 Chirila 
et al,64 and Gopal et al65 studied outcome measures within 
the samples or sub-samples of the 2 previously described 
RCTs. In details, Savitz et al62 analyzed data derived from 
the previously mentioned non-inferiority RCT comparing 
PP3M with PP1M treatment; to investigate symptomatic and 
functional remission in the DB phase of this RCT, Katz et al63 
investigated native English-speaking trial participants’ and 
English-speaking investigators’ judgments about paliperidone 
formulations and adherence; Chirila et al64 compared occupa-
tional status and health care resource use between treatment 
groups (PP3M vs placebo and PP3M vs PP1M), using data 
from the whole samples of the 2 RCTs and Gopal et al65 
evaluated caregiver burden in the 2 RCTs. Weiden et al66 
made a post-hoc analysis comparing median time to relapse 
across the treatment withdrawal arms of 3 different RCTs 
(Kramer et al,67 Hough et al,68 and Berwaerts et al60), which 
compares the 3 formulations of paliperidone with placebo. 
Joshi et al69 performed an observational retrospective cohort 
study, using pharmacy and medical claims data of the 
Symphony Health Solutions database from May 2014 to 
September 2017. This study described baseline character-
istics and treatment patterns of patients with schizophrenia 
initiated on PP3M in a real-world setting in the USA.
Discussion
Overview of pharmacology, PKs of 
paliperidone palmitate 3-monthly injection
Formulation properties
PP3M contains a racemic mixture of the active ingredient 
paliperidone (9-OH risperidone), an atypical antipsychotic 
belonging to the chemical class of benzisoxazole derivatives, 
Total records
n=38Search
Screening
Eligibility
Inclusion
Summary
Records about PP3M
n=25
Records out of topic
n=13
Records in English
n=22
22 records in English:
– 4 about PK
– 9 about clinical assessment
– 2 cost-effectiveness
   analyses
– 6 reviews
– 1 report – 4 articles about PK
– 2 cost-effectiveness analysis
– 6 reviews
– 1 report 9 articles about clinical
assessment:
– 1 OCT
– 2 RCTs
– 5 articles based on RCTs
– 1 observational study
Records in other languages
n=3 
Figure 1 Literature search flowchart.
Abbreviations: OCT, open-label clinical trial; PK, pharmacokinetics; PP3M, paliperidone palmitate 3-month; RCT, randomized controlled trial.
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Table 1 Clinical studies about PP3M
Study Aims Design, data sources and 
duration
Sample features Main results
Ravenstijn 
et al59
To assess PP3M:
•	 PK
•	 Safety
•	 Tolerability
Design: OCT
•	 Phase i study
•	 Multicenter
•	 Randomized
•	 Open-label
•	 Parallel-group
Duration: from 12.2 to 
18.2 months
328 patients aged 18–65 years
with:
•	 Schizophrenia or schizoaffective 
disorder (DSM-iv)
•	 PANSS total score of #70
without:
•	 Substance dependence nor history of 
suicide attempt within 12 months
•	 History of NMS or TD
Safety and tolerability: 
similar to those of PP1M
PK: results support a once 
every 3 months dosing 
interval
Berwaerts 
et al60
To assess PP3M:
•	 Efficacy
•	 Safety
Design: RCT
PP3M vs placebo:
•	 Phase iii study
•	 Multicenter
•	 Randomized
•	 Open-ended DB final phase
Duration of DB phase 
(median time):
•	 5.6 months in the PP3M arm
•	 4.9 months in the placebo arm
506 enrolled patients from 8 western and 
Asian countries, aged 18–70 years, with:
•	 Schizophrenia (DSM-iv-TR) for at least 
1 year before screening
•	 PANSS total score of #120 at screening
without:
•	 Significant risk of suicidal behavior
•	 History of substance dependence within 
6 months
•	 History of NMS or TD
305 patients randomized in the DB phase
Efficacy: compared with 
placebo PP3M significantly 
delayed time to relapse
Safety: profile consistent 
with other marketed 
paliperidone formulations
Savitz 
et al61
To test the non-
inferiority of PP3M 
to PP1M
Design: RCT
PP3M vs PP1M:
•	 Phase iii study
•	 Multicenter
•	 DB final phase
•	 Parallel-group
•	 Non-inferiority design
Duration of the DB phase: 
11.2 months
1,429 enrolled patients from 26 western 
and Asian countries, aged 18–70 years, 
women: postmenopausal, surgically 
sterile, or adequate contraception
Men: adequate contraception
with:
•	 Schizophrenia (DSM-iv)
•	 PANSS total score between 70 and 120
without:
•	 Any unstable or significant medical or 
neurological illness
•	 Morbid obesity (BMi .40 kg/m2)
•	 Mental retardation
•	 Risk factors for prolonged QT interval, 
torsade de pointes, or sudden death
•	 History of intolerability, hypersensitivity, 
or lack of response to risperidone or 
paliperidone
1,016 patients entered the DB phase
842 patients completed the DB phase
PP3M was non-inferior to 
PP1M in:
•	 Relapse rates
•	 Changes in PANSS scores, 
CGi-S score and PSP 
score
Savitz 
et al62
To assess 
symptomatic and 
functional remission 
achieved following 
PP3M vs PP1M 
treatment
Design: RCT
PP3M vs PP1M non-inferiority 
design
Data sources: Savitz et al study61
Duration: during DB phase, 
11.2 months
The same as Savitz 2016 study61 •	 PP3M was non-inferior to 
PP1M in
•	 Symptomatic remission 
(Andreansen’s criteria)
•	 Functional remission (PSP)
During last 6 months of the 
DB phase
Katz 
et al63
To quantify 
Berwaerts et al60 
or Savitz et al61 
RCT participants’ 
and investigators’ 
judgments about 
paliperidone 
formulations and 
adherence
Design: two discrete-choice 
experiment surveys:
•	 One for patients
•	 One for psychiatrists
Duration: cross-sectional study
438 english-speaking physicians who 
participate as investigators in Berwaerts 
et al60 and/or Savitz et al61 studies
214 english-speaking patients enrolled in 
Australia, Canada and the USA among 
the participants of Berwaerts et al60 and 
Savitz et al61 trials
Patients and physicians 
preferred LAis over oral 
antipsychotics
Physicians showed a greater 
preference for 3-month over 
1-month LAi antipsychotic
(Continued)
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derived from risperidone.70,71 PP is the palmitate salt ester of 
paliperidone. It is very slightly soluble in polar solvent.70,71 
Tiny drug crystals are created and dispersed in an aqueous 
suspension (NanoCrystal technology). These crystals are 
nanoparticles, usually defined as having a size between 
1 and 1,000 nm. These tiny drug crystals are dispersed in 
an aqueous suspension (nanosuspensions), which is the LAI 
formulation of PP.72 The PP3M formulation utilizes Nano-
Crystal technology similar to the PP1M but with increased 
particle size, allowing an extended sustained release.59 These 
nanoparticles dissolve slowly after intramuscular (IM) injec-
tion before being hydrolyzed to paliperidone by the esterases 
Table 1 (Continued)
Study Aims Design, data sources and 
duration
Sample features Main results
Chirila 
et al64
To compare 
occupational status 
and health care 
resource use between 
treatment groups 
(PP3M vs placebo and 
PP3M vs PP1M) in 
Berwaerts et al60 or 
Savitz et al61 trials
Design: longitudinal survey
Data sources: Berwaerts et al60 
and Savitz et al61 studies. Data 
deriving from these two RCTs 
were analyzed separately 
according to the design of the two 
original studies
Duration: the same of Berwaerts 
et al60 and Savitz et al61 studies
305 patients who were randomized in the 
DB phase in Berwaerts et al study60
842 patients who completed the DB phase 
in Savitz et al study61
work: no difference 
observed (only a small 
number of patients changed 
their occupational status 
during the studies)
Hospitalization: higher rate 
in the placebo group, no 
difference between PP3M 
and PP1M
Gopal 
et al65
To evaluate caregiver 
burden in Berwaerts 
et al60 and Savitz 
et al61 RCTs
Design: longitudinal survey, with 
a mirror image analysis from a 
post-hoc analysis of pooled data
Data sources: data derived from 
Berwaerts et al60 and Savitz et al61 
studies
Duration: the same of Berwaerts 
et al60 and Savitz et al61 studies
1,496 caregivers of the patients who 
participate to Berwaerts et al60 and 
Savitz et al61 studies
Caregivers who had at least 1-hour 
contact with the patient per week
Both PP1M and PP3M 
may alleviate the caregiver 
burden
The mirror image analysis 
showed that switching 
from an oral antipsychotic 
to either PP1M or PP3M 
can significantly reduce 
caregiver burden
weiden 
et al66
To evaluate the 
effect of OP, PP1M 
and PP3M on 
times to relapse 
following medication 
discontinuation
Design and data sources:
•	 Data drawn from Kramer et al,67 
Hough et al,68 and Berwaerts 
et al60 DB RCTs comparing three 
paliperidone formulations (OP, 
PP1M and PP3M) with placebo
•	 Post-hoc analysis of pooled data
•	 Survival analysis of schizophrenia 
relapse in each placebo arm
Duration: the same of Kramer 
et al,67 Hough et al,68 and Berwaerts 
et al60 studies
101 patients who were randomized in 
the placebo arm during the DB phase of 
Kramer et al study67
203 patients who were randomized in 
the placebo arm during the DB phase of 
Hough et al study68
145 patients who were randomized in 
the placebo arm during the DB phase of 
Berwaerts et al study60
50% of patients who 
withdrew treatment 
from OP, PP1M or PP3M 
remained relapse free 
for ~2, 6, and 13 months, 
respectively
The relapse risk, in terms 
of hazard ratio, was 
2.08-fold higher for patients 
discontinuing PP1M then for 
those discontinuing PP3M
Joshi 
et al69
To describe baseline 
characteristics and 
treatment patterns 
of patients with 
schizophrenia 
initiated on PP3M in a 
real-world setting
Design:
•	 Observational retrospective 
longitudinal study
•	 Cohort study
•	 Index date: the date of the first 
approved claim for PP3M
Data sources: pharmacy and 
medical PP3M claims from 
May 2014 to September 2016 in 
the Symphony Health Solutions 
database
Duration: 12 months of continuous 
clinical activity prior to the 
index date
7,160 adult patients (100%) with at least 
one approved PP3M claim 5,362 patients 
(74.9%) had continuous clinical activity for 
at least 12 months prior to the index date
1,545 patients (21.6%) also had at least 
one schizophrenia diagnosis anytime 
during the study period and were included 
in the study (over all PP3M cohort)
1,063 patients (14.8%) had the dose 
transition done as labeled (per label 
PP3M cohort)
Patients initiated on PP3M 
demonstrated decreased 
health care resource 
utilization and increased 
adherence in quarters closer 
to PP3M initiation
These patients were 
persistent on their PP3M 
treatment
Abbreviations: BMi, body mass index; CGi-S, Clinical Global impression-Severity; DB, double blind; DSM-iv, Diagnostic and Statistical Manual of Mental Disorders-iv; DSM-
iv-TR, Diagnostic and Statistical Manual of Mental Disorders-iv Text Revision; LAi, long-acting injectable; NMS, neuroleptic malignant syndrome; OCT, open-label clinical trial; 
OP, oral paliperidone; PANSS, Positive and Negative Syndrome Scale; PK, pharmacokinetics; PP1M, paliperidone palmitate 1-month; PP3M, paliperidone palmitate 3-month; 
PSP, Personal and Social Performance; RCT, randomized controlled trial; TD, tardive dyskinesia.
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present in muscle tissue. Then paliperidone diffuses into the 
systemic circulation.72,73 PP3M is available in dose strengths 
of 273, 410, 546 and 819 mg paliperidone palmitate that 
undergo hydrolysis, resulting in dose strengths of 175, 263, 
350 and 525 mg of paliperidone, respectively.72
Pharmacodynamics
Therapeutic efficacy of paliperidone likely occurs through 
its antagonism of both central dopamine D2 and serotonin 
5-HT2A receptors. Plasma concentrations of 10–17 ng/mL 
were estimated to correspond to 70%–80% occupancy of 
D2 receptors.74 A D2 receptor occupancy of 65%–80% is 
generally considered optimal, with levels exceeding this 
conferring an increased risk of extrapyramidal symptoms.75 
Paliperidone is also an antagonist at α1- and α2-adrenergic 
receptors and H1 histaminergic receptors.75,76 This activity 
profile of paliperidone may explain some of the potential 
adverse effects of the drug, such as orthostatic hypotension 
and weight gain.76 Unlike risperidone, paliperidone does 
not block beta adrenoceptors, muscarinic cholinocep-
tors or peptidergic receptors. This receptor profile, more 
selctive than the one of risperidone, could avoid further 
side effects.70
Pharmacokinetics
Nanoparticles of PP3M dissolve slowly after IM injec-
tion; release starts as early as day 1 and lasts for up to 
18 months.72 The paliperidone plasma concentration time 
profiles for the corresponding PP1M and PP3M doses are 
similar. The principal differences concern the pre-dose 
plasma concentrations of PP3M: they are 21% lower than 
the concentrations observed following PP1M administra-
tion. Mean peak-to-trough ratios are higher following PP3M 
administration (range: 1.86–2.54) than PP1M administra-
tion (range: 1.30–1.63).59 With regard to metabolism and 
elimination, information from the studies of oral paliperidone 
are reported: ~59% of a single dose of the drug is excreted 
unchanged in the urine; ~80% of the radioactivity related 
to a single oral dose of 14C paliperidone is recovered in the 
urine and 11% in the feces, indicating a lack of extensive 
hepatic metabolization.70 Results obtained in in vitro stud-
ies suggest that CYP2D6 and CYP3A4 may be implicated 
in the metabolism of paliperidone, although no evidence of 
their role derive from in vivo studies: inhibitors or induc-
ers of CYP2D6 and CYP3A4 do not significantly influence 
paliperidone plasma levels and no significant induction or 
inhibitory properties of paliperidone on the cytochrome 
system have been demonstrated.59
Dosing and switching
PP3M injections should be started at a dose 3.5-fold multiple 
of the preceding dose of PP1M, and administered in either 
the deltoid or the gluteal muscle at the time scheduled for 
the next PP1M dose.72 Available marketed doses are listed 
in Table 2.
Treatment with PP3M should only be initiated in patients 
who had adequately responded to and tolerated treatment with 
PP1M for at least 4 months.72 Due to the slow release profile, 
treatment with PP3M is not indicated for use in acutely symp-
tomatic patients or in patients who are transitioning from 
oral or other, non-PP1M, LAI antipsychotic therapy.72 It is 
recommended that the last 2 PP1M doses prior to switching to 
PP3M are the same and patients are supposed to be clinically 
stable at the end of the PP1M dosing before transitioning to 
PP3M.72 According to PK simulations, during maintenance 
therapy of PP3M, changes in plasma concentrations allow a 
flexible dosing window of 2 weeks for regularly scheduled 
3-monthly injections (Table 3).72
PP3M injection procedure
One significant difference between the preparation of PP1M 
and PP3M is the force of shaking required to re-suspend 
the syringe contents. The PP3M syringe must be shaken 
vigorously for at least 15 seconds with a loose wrist before 
Table 2 Conversion between PP1M and PP3M doses
PP1M dose PP3M dose
Paliperidone 
palmitate (mg)
Paliperidone 
(mg eq)
Paliperidone 
palmitate (mg)
Paliperidone 
(mg eq)
78 50 273 175
117 75 410 263
156 100 546 350
234 150 819 525
Note: Data from european Medicine Agency.83
Abbreviations: mg eq, milligram equivalent; PP1M, paliperidone palmitate 1-month 
injection; PP3M, paliperidone palmitate 3-month injection.
Table 3 Management of missed PP3M injections
Time from the last 
PP3M injection, months
Management with PP injectable 
formulations
3.5–4 Resume PP3M injection as soon as possible
4–9 Reinitiate the regimen with PP1M on 
days 1 and 8; reinitiate PP3M injections 
after 4 weeks
.9 Reinitiate the regimen with PP1M on 
days 1 and 8, followed by at least 3 doses 
of PP1M; resume PP3M injections on a 
3-monthly cycle (full new cycle)
Note: Data from european Medicine Agency.83
Abbreviations: PP, paliperidone palmitate; PP1M, paliperidone palmitate 1-month 
injection; PP3M, paliperidone palmitate 3-month injection.
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injecting the formulation to ensure a homogenous suspen-
sion. Improper shaking could result in clumping and inability 
to express the entire medication content from the syringe 
barrel.72 Furthermore, a suitable syringe must be used: in the 
RCT comparing PP3M and PP1M, the use of a shorter syringe 
and the consequent lower dose administration of PP3M 
caused the exclusion of some patients from the study.61,62
Clinical efficacy, safety and tolerability of 
PP for schizophrenia
Efficacy and hospitalization rate
Efficacy of PP3M was evaluated against placebo60 and in 
terms of non-inferiority against PP1M61 in 2 different DB 
RCTs summarized in Table 1. The first study was stopped 
by an independent data monitoring committee for greater 
efficacy of PP3M compared to placebo: during the DB phase, 
29% of patients in the placebo group experienced a relapse 
event against 9% in the group receiving PP3M.60 The final 
data analysis included 305 patients (PP3M: n=160; placebo: 
n=145) and showed superiority of PP3M over placebo 
in delaying time to relapse of schizophrenia symptoms 
(P,0.001; hazard ratio=3.81; 95% CI, 2.08–6.99), a result 
confirmed by Cox proportional hazards models.60 Further-
more, Weiden et al post-hoc study66 showed longer time to 
relapse after PP3M treatment discontinuation compared to 
that of oral paliperidone and PP1M: in particular, after sus-
pension of the treatment, 50% of patients treated with PP3M 
remained relapse free for ~13 months, instead of 6 months 
with PP1M treatment withdrawal. Also, according to this 
study, the relapse risk (hazard ratio) was 2.08 higher for 
patients discontinuing PP1M than for those discontinuing 
PP3M.66 However, as these data come from a descriptive 
post-hoc analysis and not a meta-analysis of the datasets of 
the three different RCTs (Kramer et al,67 Hough et al68 and 
Berwaerts et al60), caution must be used when interpreting this 
study. Furthermore, this was not a head-to-head discontinua-
tion RCT comparing oral paliperidone, PP1M and PP3M in 
the same trial; therefore, the evidence of this post-hoc analysis 
has strong study design and generalizability limitations.
The non-inferiority Phase III RCT61 demonstrated that 
PP3M-treated group had relapse rates similar to PPM1-
treated group, based on Kaplan–Meier estimates. Variations 
from DB baseline in Positive and Negative Symptom Scale 
(PANSS) total score and subscale scores, in Clinical CGI-S 
and in PSP scores were similar in the two experimental 
groups.61 Furthermore, PP3M and PP1M treatments showed 
comparable symptomatic (defined according to Andreasen’s 
criteria on PANSS) and functional remissions (PSP .70) 
during the last 6 months of DB phase. In addition, most 
patients who achieved remission at DB baseline maintained 
their remission status throughout the DB phase.62
Moreover, health care resource use was studied in the 
2 described RCTs60,61 in terms of hospitalization odds.64 The 
placebo group showed a higher rate of hospitalization for 
either psychiatric and social reasons or social reason alone 
compared to PP3M.64 No difference in terms of hospitaliza-
tions was observed between PP3M and PP1M groups.64
Safety and tolerability
Safety and tolerability were examined in the 2 previously 
described RCTs and in the Phase I OCT.59 The latter one 
showed that headache and nasopharyngitis were the most 
common (.7%) treatment-emergent adverse events (TEAEs) 
and described a safety and tolerability profile similar to those 
of PP1M.59 Compared with placebo, PP3M treatment demon-
strated a similar proportion on TEAEs developed during the 
DB phase of the study: 62% of the subjects who were treated 
with PP3M injections and 58% of the subjects who received 
placebo injections had at least one TEAE. TEAEs noted 
more frequently in the group receiving PP3M than in the 
placebo group were headache (9% vs 4%), weight increase 
(9% vs 3%), nasopharyngitis (6% vs 1%) and akathisia 
(4% vs 1%).60 In the non-inferiority Phase III RCT, safety 
and tolerability profiles of PP3M and PP1M were comparable 
over the whole DB phase of the study. Withdrawal rates due 
to TEAEs were low and comparable for both treatments.61 
Serious TEAEs were mostly of a psychiatric nature and 
similar between both groups.61 Weight gain, nasopharyngitis 
and anxiety were the most common TEAEs in both groups.61 
Other TEAEs such as extrapyramidal symptoms, suicidality, 
agitation and aggression, somnolence and sedation, tachy-
cardia, orthostatic hypotension, QTc interval prolongation, 
potentially prolactin-related and weight gain-related TEAEs 
had a similar frequency in both experimental groups.61
Pregnancy
With its release during 18 months from the injection, PP3M 
makes more likely fetal exposition to paliperidone. However, 
few data about paliperidone effects in pregnancy are available 
in scientific literature. Two case reports of women in treatment 
with PP1M during pregnancy reported no congenital malfor-
mation and no perinatal complications of the newborns.77,78
Other features of PP3M and ethical 
implications
Quality of life, satisfaction and adherence
To our knowledge, no studies about quality of life, sat-
isfaction and adherence of PP3M-treated patients with 
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schizophrenia have been performed, yet. Longer follow-up 
studies should be carried out in order to compare switching 
from PP1M to PP3M treatment.
Caregiver burden
A study by Gopal et al65 showed that switching from an oral 
antipsychotic to either PP1M or PP3M can significantly 
reduce caregiver burden. This mirror image study was per-
formed on data derived from the non-inferiority Phase III 
RCT comparing PP1M and PP3M.61 For this reason, both 
treatment groups received a monthly injection and caregiver 
burden reduction because diminished number of administra-
tions was not detectable.65 To our knowledge, no studies on 
this topic in the transition from PP1M to PP3M in a real-
world setting are available.
Antipsychotic preference according to 
formulation
Katz et al63 analyzed preferences between oral antipsychotic 
treatments, PP1M and PP3M with a survey performed by 
English native speaking and English-speaking physicians 
who participated in the 2 RCTs60,61 as previously described.
According to this study, patients and physicians preferred 
LAIs over oral antipsychotics and were willing to accept 
reduced efficacy in exchange for switching from an oral 
formulation to an LAI. Physicians showed a greater prefer-
ence for 3-month over 1-month LAI.63
Occupational status variation
Chirila et al64 described the occupational status of patients 
who participated in the 2 RCTs60,61 as previously described. 
According to that study, no significant differences in terms of 
variation of the occupational status were observed between 
PP3M and placebo and PP3M and PP1M treatments, prob-
ably because of the short time of follow-up and consequently 
the small number of patients who changed their occupational 
status during the 2 trials.64 Although not statistically signifi-
cant, at the end of the follow-up period (from week 41 until 
week 53), improvement from baseline in occupational status 
was slightly higher in the PP3M than in the PP1M group.64
ethical implications
Both the RCT comparing PP3M with placebo60 and the RCT 
comparing PP3M with PP1M61 were conducted in compli-
ance with the Declaration of Helsinki, consistent with Good 
Clinical Practices and applicable regulatory requirements 
and with the approval of independent ethical committees of 
the participant center. Nonetheless, some ethical critics were 
made against these studies. First of all, comparing a new drug 
with placebo might be considered ethically debatable and 
clinically irrelevant when effective agents are available.79 
In this particular case, the European Medicines Agency 
(EMA) pointed out the relevance of placebo-controlled 
studies when assessing the efficacy of new LAIs, arguing 
that recent schizophrenia trials showed only minimal differ-
ences between active treatments and placebo, and therefore 
an assessment of the absolute effect is required to establish 
efficacy.80 With reference to the study comparing PP3M and 
PP1M, it has been pointed out that, as there is no validated 
and shared method of choice of the non-inferiority margin, 
the demonstration of non-inferiority leaves uncertainty on 
whether the 2 drugs are really equivalent and does not estab-
lish whether the new drug tested is associated with additional 
benefits over the control.79
Advantages and disadvantages of PP3M 
compared with PP1M
Advantages and disadvantages of PP3M, compared with 
PP1M treatment, are summarized in Figure 2.
One of the most positive features of PP3M is notable 
that patients need to receive an injection just 4 times per 
year. The lower number of injections is more comfortable 
for patients, especially for those patients who cannot easily 
reach the place of administration. Furthermore, less time 
is needed for drug administration so that saved time and 
resources can be available for other therapeutic activities, 
for example, rehabilitation. At the same time, psychiatric 
services with poor human resources should control the risk 
to visit the patient exclusively 4 times a year on the day of 
PP3M administration and not according to the health needs 
of the patient. In terms of costs, three doses of PP1M cost 
as much as the equivalent dose of 1 PP3M injection, but 
the administration costs are reduced to one-third. More-
over, 2 economic studies evaluated cost-utility and cost-
effectiveness simulations on the use of PP3M in Spain and 
in the Netherlands.81,82 According to these studies, PP3M 
resulted to be cost-effective for treating chronic schizophre-
nia and dominated PP1M in all analyses.81,82
Finally, PP3M administration protocol admits more 
flexible delays in PP3M injections interval compared with 
PP1M. In fact, according to PP3M administration regimen, 
2 weeks of delays after 3 planned months of inter-injections 
interval can be tolerated instead of 1 week with PP1M.
The main disadvantages of PP3M can be summarized as 
follows. First of all, despite the tolerance demonstrated by 
patients during the PP1M phase of treatment, adverse events 
related to paliperidone therapy might appear during PP3M 
treatment. The control of these side effects, especially if 
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starting soon after a PP3M administration, could be a clinical 
challenge for psychiatrists but, above all, a real health 
problem for patients. In addition, a 3-month dosing interval 
may induce psychiatrists to visit patient less frequently, for 
example only in concomitance with PP3M administration. 
Even if PK studies demonstrated a similar exposure to pali-
peridone with PP3M and PP1M, a 3.5-fold higher dose of 
PP3M is equivalent to a single dose of PP1M. In other words, 
a larger quantity of PP is injected in patients treated with 
PP3M. These data, in addition to the known higher plasmatic 
mean peak-to-trough ratio of PP3M, could lead to long-term 
adverse effects, somewhat different from those of PP1M.
PP3M injections need more technical carefulness to be 
correctly administered compared with PP1M procedure. In 
fact, a longer period of shaking and a longer injecting proce-
dure are required. Finally, the larger volume administered with 
PP3M could be more painful in the injected muscle tissue.
Possible study designs to further 
assess PP3M
Further studies are needed to asses PP3M features more clearly. 
Some proposals of study design are described in Figure 3.
To our knowledge, the only observational study on PP3M 
is a retrospective cohort study that chose the date of the 
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Figure 2 Comparison between PP3M and PP1M pros and cons.
Abbreviations: Ae, adverse event; PP1M, paliperidone palmitate 1-month; PP3M, paliperidone palmitate.
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??????????????????????
????????????????????????
???????????????????????????????????????????????????????
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Figure 3 Some possible study designs needed to further assess PP3M.
Abbreviations: PP1M, paliperidone palmitate 1-month; PP3M, paliperidone palmitate 3-month.
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first approved claim for PP3M as the index date.69 Accord-
ing to its experimental design, this study does not inform 
about the effect of PP3M treatment. In this scenery, large 
pragmatic trials and mirror studies on real-world patients 
switching from PP1M to PP3M would be useful in defining 
advantages and disadvantages of PP3M confronted with 
PP1M. Furthermore, 2-arm head-to-head superiority trials 
could directly compare PP3M with PP1M and with other 
SGA-LAIs. Regardless of the study design adopted, longer 
follow-ups are needed to study PP3M treatment safety and 
impact on patients’ adherence, functioning, quality of life 
and satisfaction. Finally, further studies are necessary to 
determine which subgroups of patients would most benefici-
ate from PP3M treatment.
Conclusion
In conclusion, PP3M is the only 3-month LAI antipsychotic 
available on the market. This makes it a unique option of 
treatment, which can be chosen both in early and advanced 
phases of illness. Nonetheless, further studies are needed to 
assess long-term safety, impact on quality of life and on func-
tioning and to define patients’ sub-populations that would 
most beneficiate from this new option of treatment.
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